Selective P2X7 receptor antagonists for chronic inflammation and pain
Open Access
- 21 June 2008
- journal article
- review article
- Published by Springer Nature in Purinergic Signalling
- Vol. 5 (1), 63-73
- https://doi.org/10.1007/s11302-008-9110-6
Abstract
ATP, acting on P2X7 receptors, stimulates changes in intracellular calcium concentrations, maturation, and release of interleukin-1β (IL-1β), and following prolonged agonist exposure, cell death. The functional effects of P2X7 receptor activation facilitate several proinflammatory processes associated with arthritis. Within the nervous system, these proinflammatory processes may also contribute to the development and maintenance of chronic pain. Emerging data from genetic knockout studies have indicated specific roles for P2X7 receptors in inflammatory and neuropathic pain states. The discovery of multiple distinct chemical series of potent and highly selective P2X7 receptor antagonists have enhanced our understanding of P2X7 receptor pharmacology and the diverse array of P2X7 receptor signaling mechanisms. These antagonists have provided mechanistic insight into the role(s) P2X7 receptors play under pathophysiological conditions. In this review, we integrate the recent discoveries of novel P2X7 receptor-selective antagonists with a brief update on P2X7 receptor pharmacology and its therapeutic potential.Keywords
This publication has 57 references indexed in Scilit:
- Painful Purinergic ReceptorsJournal of Pharmacology and Experimental Therapeutics, 2007
- Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X7Receptor Antagonists/Interleukin-1β InhibitorsJournal of Medicinal Chemistry, 2007
- Discovery of P2X7 receptor‐selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain statesBritish Journal of Pharmacology, 2007
- Characterization of a selective and potent antagonist of human P2X7 receptors, AZ11645373British Journal of Pharmacology, 2006
- A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the RatPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2006
- Purinergic signalling in neuron–glia interactionsNature Reviews Neuroscience, 2006
- Interleukin-1αβ gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative painBehavioural Brain Research, 2006
- Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X7 receptor−/− miceNeuroReport, 2004
- Mitogen-Activated Protein Kinase and Caspase Signaling Pathways Are Required for P2X7Receptor (P2X7R)-Induced Pore Formation in Human THP-1 CellsJournal of Pharmacology and Experimental Therapeutics, 2003
- Extracellular ATP Activates Transcription Factor NF-κB through the P2Z Purinoreceptor by Selectively Targeting NF-κB p65 (RelA)The Journal of cell biology, 1997